Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients
- Registration Number
- NCT01767493
- Lead Sponsor
- Institute for Neurodegenerative Disorders
- Brief Summary
The purpose of this study is to evaluate the feasibility of \[18F\]Florbetapir positron emission tomography (PET) for assessment of demyelination in the patients with relapsing remitting multiple sclerosis.
- Detailed Description
The underlying goal of this study is to assess the feasibility of \[18F\]Florbetapir as an imaging tool to detect demyelination in the brain of MS research participants and compare to similarly aged healthy subjects.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 19
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description [18F]Florbetapir PET imaging [18F]Florbetapir PET imaging \[18F\]Florbetapir and PET imaging
- Primary Outcome Measures
Name Time Method Total Number of Lesions Detected by [18F]Florbetapir PET 1 year This study demonstrates the feasibility of\[18F\]Florbetapir PET for identifying demyelinating lesions in relapsing-remitting MS patients. It was expected that lesion size played a factor in identifying white matter lesions with those smaller than 5 mm less evident on PET. Using spherical volumes of interest the extent of reduction in the white matter uptake can be reliably quantified. This requires careful attention to techniques for sampling in both the lesions and white matter control regions for the subject.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Institute for Neurodegenerative Disorders
🇺🇸New Haven, Connecticut, United States